EMPASHIELD M 25/1000 10'S

About

EMPASHIELD M 25/1000 combines empagliflozin (an SGLT2 inhibitor) and metformin (a biguanide) to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin works by inhibiting the sodium-glucose co-transporter 2 in the kidneys, leading to increased glucose excretion in the urine and subsequently lowering blood glucose levels. It also offers significant cardiovascular and renal protective benefits, reducing the risk of cardiovascular death, hospitalization for heart failure, and progression of kidney disease. Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. This dual-action medication provides comprehensive blood sugar management, addressing multiple pathways involved in glucose dysregulation. It is typically used as an adjunct to diet and exercise, either as initial therapy or in patients inadequately controlled on monotherapy or other antidiabetic agents.

Uses

• Management of type 2 diabetes mellitus
• Improvement of glycemic control
• Reduction of cardiovascular risk in type 2 diabetes patients with established cardiovascular disease
• Reduction of risk of kidney disease progression in type 2 diabetes patients

Directions For Use

Take orally with meals, usually twice daily, or as directed by your physician. Swallow the tablet whole.

Benefits

• Comprehensive blood sugar control
• Significant reduction in HbA1c levels
• Supports weight management
• Reduces risk of major cardiovascular events
• Provides renal protective benefits
• Convenient combination therapy

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Urinary tract infections
• Genital yeast infections
• Increased urination
• Thirst
• Dehydration
• Hypoglycemia (when combined with insulin/sulfonylureas)
• Ketoacidosis (rare)
• Lactic acidosis (rare, with metformin)
• Dizziness

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of lactic acidosis, a serious side effect associated with metformin.
• Pregnancy - Generally not recommended during pregnancy. Consult your doctor immediately if you become pregnant or plan to conceive.
• Breastfeeding - Not recommended during breastfeeding as the components may pass into breast milk. Consult your doctor.
• Liver - Use with caution in patients with liver conditions. Metformin is contraindicated in severe hepatic impairment due to increased risk of lactic acidosis.
• Kidney - Dose adjustment is necessary for empagliflozin based on eGFR, and metformin is contraindicated in severe renal impairment. Regular kidney function monitoring is crucial.
• Lung - No specific direct lung contraindication, but severe respiratory conditions may increase the risk of lactic acidosis with metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.